Published in Stem Cell Reports on February 11, 2016
Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle (2016) 0.81
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Front Cell Dev Biol (2017) 0.80
Nuclear reprogramming of cancer stem cells: Corrupting the epigenetic code of cell identity with oncometabolites. Mol Cell Oncol (2016) 0.75
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
High density DNA methylation array with single CpG site resolution. Genomics (2011) 10.35
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
Epigenetic signatures of stem-cell identity. Nat Rev Genet (2007) 3.56
Epigenetic reprogramming in cancer. Science (2013) 3.47
The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer (2011) 3.42
SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Theoretical analysis of epigenetic cell memory by nucleosome modification. Cell (2007) 3.17
Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell (2014) 2.82
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev (2012) 2.70
Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell (2013) 2.69
Metabolic regulation of epigenetics. Cell Metab (2012) 2.55
Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells (2009) 2.48
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Genome-wide characterization of the routes to pluripotency. Nature (2014) 2.34
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet (2013) 1.98
Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem (2002) 1.92
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
The nexus of chromatin regulation and intermediary metabolism. Nature (2013) 1.87
Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 1.78
Epigenetics of reprogramming to induced pluripotency. Cell (2013) 1.73
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res (2012) 1.63
High-resolution analysis with novel cell-surface markers identifies routes to iPS cells. Nature (2013) 1.48
Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol (2013) 1.47
Cancer: pathological nuclear reprogramming? Nat Rev Cancer (2014) 1.17
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell (2015) 1.13
Epigenetic mechanisms that regulate cell identity. Cell Stem Cell (2010) 1.12
Interactions between epigenetics and metabolism in cancers. Front Oncol (2012) 1.11
An improved method for generating and identifying human induced pluripotent stem cells. Methods Mol Biol (2010) 1.07
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem (2012) 1.06
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene (2013) 1.00
The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One (2010) 0.99
Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience (2014) 0.91
Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget (2014) 0.91
A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks. PLoS Comput Biol (2014) 0.90
Mathematical approaches to modeling development and reprogramming. Proc Natl Acad Sci U S A (2014) 0.87
Epigenetics and cancer metabolism. Cancer Lett (2013) 0.86
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget (2015) 0.84
Epigenetic mechanisms of tumorigenicity manifesting in stem cells. Oncogene (2014) 0.81
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget (2015) 0.80
New balance in pluripotency: reprogramming with lineage specifiers. Cell (2013) 0.80
Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. J Am Soc Mass Spectrom (2015) 0.79
Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle (2014) 0.79